Successfully treatment by eribulin in visceral crisis: a case of lymphangitic carcinomatosis from metastatic breast cancer
Open Access
- 20 August 2018
- journal article
- case report
- Published by Springer Nature in BMC Cancer
- Vol. 18 (1) , 839
Abstract
Metastatic breast cancer (MBC) rest an incurably disease associated with bad prognosis and a median overall survival of 23–31 months. There are several treatment options including chemotherapy and sometimes endocrine therapy. Currently, there is no standard treatment for patients with MBC who have already benefited from anthracyclines and taxanes therapy. Many drugs like capecitabine, eribulin, gemcitabine, vinorelbin and liposomal doxorubicin are conventionally used as monotherapy. One important complication from MBC is life threating visceral crisis that needs a fast-effective treatment. We report here a case of an evolution of metastatic breast cancer with lymphangitic carcinomatosis after taxane based chemotherapy and endocrine therapy. This 37-year-old woman was referred to our hospital with complaints of dyspnea and dry cough. There was clinical concern for visceral crisis and a chemotherapy with eribulin was initiated. Pulmonary lymphangitic carcinomatosis disappeared and the patient achieved a good partial response. We reported a case of rapid, positive treatment response using eribulin on metastatic breast cancer with visceral crisis and we could quoted others. Therefore, eribulin may be an appropriate chemotherapeutic option in instances requiring rapid symptom control.Keywords
This publication has 16 references indexed in Scilit:
- Treatment of Metastatic Breast Cancer in a Real-World Scenario: Is Progression-Free Survival With First Line Predictive of Benefit From Second and Later Lines?The Oncologist, 2015
- Pulmonary Lymphangitic Carcinomatosis From Metastatic Gastric Adenocarcinoma: Case ReportJournal of Osteopathic Medicine, 2015
- Management of patients with hormone receptor–positive breast cancer with visceral disease: challenges and treatment optionsCancer Management and Research, 2015
- Incidence and management of mTOR inhibitor-associated pneumonitis in patients with metastatic renal cell carcinomaAnnals of Oncology, 2012
- A Phase II Study of Halichondrin B Analog Eribulin Mesylate (E7389) in Patients with Advanced Non-small Cell Lung Cancer Previously Treated with a Taxane: A California Cancer Consortium TrialJournal of Thoracic Oncology, 2012
- Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised studyThe Lancet, 2011
- Eribulin Induces Irreversible Mitotic Blockade: Implications of Cell-Based Pharmacodynamics for In vivo Efficacy under Intermittent Dosing ConditionsCancer Research, 2011
- Trends in Survival Over the Past Two Decades Among White and Black Patients With Newly Diagnosed Stage IV Breast CancerJournal of Clinical Oncology, 2008
- A Patient with Pulmonary Lymphangitic Carcinomatosis Successfully Treated with TS-1 and CisplatinInternal Medicine, 2007
- [Carcinomatous lymphangitis].1999